Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Neximmune Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
NEXI
Nasdaq
8731
https://www.neximmune.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Neximmune Inc
NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Feb 6th, 2024 9:42 pm
NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Feb 2nd, 2024 7:00 pm
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
- Dec 1st, 2023 12:41 pm
NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes
- Oct 24th, 2023 12:00 pm
NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting
- Oct 19th, 2023 12:00 pm
NexImmune Announces 1-for-25 Reverse Stock Split
- Oct 18th, 2023 3:30 pm
NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy
- Aug 31st, 2023 8:45 pm
NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates
- Aug 10th, 2023 8:01 pm
NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting
- Jun 5th, 2023 12:01 pm
NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting
- May 22nd, 2023 8:01 pm
NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates
- May 15th, 2023 8:01 pm
Scroll